STONY BROOK, N.Y. April 6, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has been awarded a safeCircle™ health services contract from a New York City-based investment management firm. Contract terms [...]
STONY BROOK, N.Y. - March 23, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in cell-free, enzymatic DNA production, today announced that CEO Dr. James A. Hayward is invited to present at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from [...]
STONY BROOK, N.Y. and TORONTO, CANADA - March 14, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and Spindle Biotech Inc. (“Spindle Biotech”), a company focused on the development of a novel, high yield, and low-cost RNA production systems, today announced that the two [...]
LAURA PÉREZ | 7 MARCH, 2022 If PCR tests already exist to detect Covid, why not do PCR’s to trace cotton? That was the question MeiLin Wan, vice president of textiles at Applied DNA Sciences, posed to BOF. Of course, making such a utopia a reality requires overcoming some challenges to achieve an effective method [...]
By Crispin Argento, March 3, 2022 The recent New York Times exposé “That Organic Cotton T-Shirt May Not Be as Organic as You Think’” should not be misinterpreted as an affront to farmers who choose to grow organically or the organic agricultural philosophy—in fact, it can and should be viewed as quite the opposite. Following what [...]
STONY BROOK, N.Y. February 24, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direct offering with an institutional investor of 1,496,400 shares of common stock (or common stock equivalents) at a price of $2.80 [...]
STONY BROOK, N.Y. - February 22, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock (or common [...]
Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed [...]